How lower, capped-dose GLP-1 + GIP signaling supports long-term metabolic resilience with improved tolerability
However, both can cause gastrointestinal side effects and affect weight, requiring careful monitoring when used together
Below are examples of insulins other than NovoLog that may be used to treat type 1 or type 2 diabetes: other rapid-acting insulins, such as: insulin aspart (Fiasp) insulin glulisine (Apidra) inhaled insulin human (Afrezza) regular or short-acting insulins, such as: insulin regular (Humulin R, Novolin R) intermediate-acting insulins, such as: insulin NPH (Humulin N, Novolin N) long-acting insulins, such as: insulin degludec (Tresiba) insulin detemir (Levemir) NovoLog can cause mild or serious side effects
Monitor for nausea, dizziness, irregular heartbeat, or excessive thirst
This finding is important for product formulation: effective copper peptide products need precisely calibrated concentrations, not just "more copper peptide." Is this study considered reliable
